Login / Signup

Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis.

Novin NezamololamaErika L CrowleyMelinda J GooderhamKim A Papp
Published in: Expert opinion on investigational drugs (2020)
Evidence supports clinical efficacy, improved pruritus and an acceptable safety profile, making abrocitinib a viable alternative to conventional AD therapies. Pivotal phase III trials included subjects aged 12 years and above, providing a new mechanism of action for future treatment of adolescent and adult AD. Further investigations are required to have a thorough understanding of abrocitinib in the treatment of AD.
Keyphrases
  • atopic dermatitis
  • phase iii
  • clinical trial
  • combination therapy
  • open label
  • high intensity
  • double blind
  • study protocol